Rosetta Genomics last week published data validating its miRview Mets 2 cancer of unknown primary origin diagnostic.
In a paper published in The Oncologist, company researchers reported that the test could use microRNA signatures to identify 42 tumor types with high accuracy, maintaining the performance across patient samples.
“In the study, the assay was first validated on 509 samples of known origin in a blinded manner and demonstrated 85 percent accuracy, with the vast majority of samples resulting in a single reported origin, which was accurate in 90 percent of the cases,” Rosetta said. Clinico-pathologic evaluation validated the performance of the assay in bona fide CUP cases.
The publication comes on the heels of Rosetta's announcement that miRview Mets 2 had received Medicare coverage (GSN 5/17/2012).